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ABSTRACT 
Vasodilatation is a vital mechanism of systemic blood flow regulation that occurs during 
periods of increased energy demand. The AMP-dependent protein kinase (AMPK) is a 
serine/threonine kinase that is activated by conditions that increase the AMP-to-ATP ratio, 
such as exercise and metabolic stress. We hypothesized that AMPK could trigger 
vasodilatation and participate in blood flow regulation. Rings of thoracic aorta were isolated 
from C57Bl6 mice and mice deficient in the AMPK catalytic a1 (AMPKa1-/-) or a2 
(AMPKa2-/-) subunit and their littermate controls, and mounted in an organ bath. Aortas were 
preconstricted with phenylephrine (1mM) and activation of AMPK was induced by addition of 
increasing concentrations of 5-aminoimidazole-4-carboxamide-1-ß-D-ribofuranoside 
(AICAR). AICAR (0.1- 3mM) dose-dependently induced relaxation of precontracted 
C57BL6, AMPKa1+/+ and a2+/+ aorta (P<0.001, n= 5 to 7 per group). This AICAR induced 
vasorelaxation was not inhibited by the addition of adenosine receptor antagonists. Moreover, 
when aortic rings were freed of endothelium by gentle rubbing, AICAR still induced aortic 
ring relaxation, suggesting a direct effect of AICAR on smooth muscle cells. When aortic 
rings were pretreated with L-NMMA (30 mM) to inhibit nitric oxide synthase activity, AICAR 
still induced relaxation. Western blot analysis of C57Bl6 mice denuded aorta showed that 
AMPK was phosphorylated after incubation with AICAR and that AMPKa1 was the main 
catalytic subunit expressed. Finally, AICAR-induced relaxation of aortic rings was 
completely abolished in AMPKa1-/- but not AMPKa2-/- mice. Taken together, the results 
show that activation of AMPKa1 but not AMPKa2 is able to induce aortic relaxation in mice, 
in an endothelium and eNOS-independent manner. 
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INTRODUCTION 
AMPK is a ubiquitous serine/threonine protein kinase activated by pathological stimuli, 
such as oxidative damage, osmotic shock, hypoxia, and glucose deprivation, as well as by 
physiological stimuli such as exercise, muscle contraction, and by hormones including leptin 
and adiponectin (Hardie et al., 2003). AMPK is activated in response to decreased cellular 
energy charge (high AMP/ATP ratio) and is involved in regulating carbohydrate and fat 
metabolism (Hardie et al., 2003; Sambandam & Lopaschuk, 2003). 
AMPK exists in cells as a heterotrimeric complex composed of a catalytic subunit (a) 
and two regulatory subunits (b and g). Two a subunit isoforms exist, a1 and a2 that are 
unevenly distributed in the tissues. AMPK is expressed both in endothelial cells and in 
smooth muscle cells. The predominant isoform expressed in vascular endothelial cells is a1 
(Davis et al., 2006; Zou et al., 2004). AMPK expression in vascular smooth muscles is 
different from its expression in striated muscles (Rubin et al., 2005). Both a1 and a2 catalytic 
subunits are expressed in arterial smooth muscle cells, although their relative proportion 
differs between different arteries (Evans et al., 2006; Rubin et al., 2005). 
AMPK can be artificially activated by treatment with the AMPK activator 5-
aminoimidazole-4-carboxamide-1-ß-D-ribofuranoside (AICAR). This nucleoside is taken up 
by cells, resulting in accumulation of the monophosphorylated derivative (5-aminoimidazole-
4-carboxamide ribonucleotide; ZMP) and activation of AMPK (Corton et al., 1995). 
Treatment of human aortic smooth muscle cells or isolated rabbit aortas with AICAR induces 
phosphorylation of AMPK and of acetyl Co-A carboxylase, a key target of AMPK, resulting 
in inhibition of growth factor-induced cell proliferation (Igata et al., 2005). A target of AMPK 
is endothelial nitric oxide synthase (eNOS), an important modulator of angiogenesis and 
vascular tone. It has been clearly established that AMPK may associate with, and 
phosphorylate eNOS in cardiomyocytes and endothelial cells (Chen et al., 1999), in 
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association with the heat shock protein 90 (Davis et al., 2006), thus increasing eNOS activity 
and NO production. Direct activation of AMPK with AICAR stimulates NO synthesis in 
human aortic endothelial cells (Morrow et al., 2003). Furthermore AMPK can be activated 
independently in endothelial cells by extracellular nucleotides and adenosine through P2 
receptors and adenosine transporters (da Silva et al., 2006). Finally, metabolically challenged 
endothelium-denuded porcine carotid artery segments exhibit a rapid increase in AMPK 
activity after metabolic stress associated with the recruitment of signaling pathways that may 
regulate smooth-muscle contraction (Rubin et al., 2005). However, AICAR failed to relax 
endothelin-1 precontracted carotid artery rings in this species (Rubin et al., 2005). These data 
suggest that AMPK may play a complex role in vascular function and remodelling. However, 
the possible implication of AMPK in vasorelaxation has not at present been directly shown. 
In this study we investigated whether pharmacological activation of AMPK by AICAR 
could induce relaxation of preconstricted mouse aorta and whether this effect was mediated 
by endothelium and/or NOS activation. Furthermore, AMPK isoform specificity of AICAR-
induced relaxation was investigated in AMPKa1 and a2 knock-out mice and their littermate 
controls (Jorgensen et al., 2004; Viollet et al., 2003). The results show that activation of 
AMPKa1 induces vasorelaxation of mouse aorta in an endothelium- and NOS-independent 
manner. 
 
MATERIALS AND METHODS 
 Chemicals and materials for mechanical experiments  
The following drugs and chemicals were supplied by Sigma-Aldrich Chimie (Saint-Quentin 
Fallavier, France): acetylcholine chloride, phenylephrine, KCl, 8-(p-Sulfophenyl)theophylline 
(SPT) and 1,3-dipropyl-8-(p-sulfophenyl)xanthine (DPSX). NG-monomethyl L-arginine (L-
NMMA) was purchased from Calbiochem (EMD Biosciences, Inc, an Affiliate of Merck, 
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Darmstadt, Germany) and AICAR from Toronto Research Chemicals Inc (Toronto Canada). 
Stock solutions of these drugs were all prepared in distilled water. Further dilutions were 
prepared in Krebs-Henseleit buffer.  
 
 Animal models 
The generation of mouse knock-outs for AMPKa1 and AMPKa2 catalytic subunits has been 
described elsewhere (Jorgensen et al., 2004; Viollet et al., 2003). AMPKa1 background mice 
were C57Bl6/129Sv/ FVB-N and AMPKa2 mice were C57Bl6 background (6 backcrosses). 
All genetically modified mice were compared to their appropriate controls. Because the 
genetic backgrounds of the two models were different, adult male AMPKa1-/- or AMPKa2-/- 
and their control littermates or wild-type C57Bl6 mice (WT) were used in this study. 
Genotypes of the knock-out mice were determined by PCR with primer couples for AMPKa1 
deleted allele (forward: GGG CTG CAG GAA TTC GAT ATC AAG C and reverse: CCT 
TCC TGA AAT GAC TTC TGG TGC); for AMPKa1 wild type allele (forward: 
AGCCGACTTTGGTAAGGATG and reverse: CCCACTTTCCATTTTCTCCA); for 
AMPKa2 deleted allele (forward: GCT TAG CAC GTT ACC CTG GAT GG and reverse: 
GCA TTG AAC CAC AGT CCT TCC TC ); and for AMPKa2 wild type allele (forward: 
GCT TAG CAC GTT ACC CTG GAT GG and reverse: GTT ATC AGC CCA ACT AAT 
TAC AC). Animals were housed under temperature-controlled conditions (21°C) and had free 
access to water and to a standard mouse chow. The investigation was conducted in accordance 
with our institutional guidelines defined by the European Community guiding principles in 
the care and use of animals and French decree n° 87/848.  
 
 Functional measurements of aortic reactivity 
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Mice (n= 4–7 per group) were anesthetized by intraperitoneal injection of sodium 
pentobarbital (60 mg/kg). Thoracic aortas were dissected free and placed in ice-cold Krebs-
Henseleit buffer continuously gassed with a mixture of 95% oxygen and 5% carbon dioxide 
and containing the following in mM: NaCl 116.3, KCl 5.4, CaCl2 1.8, NaH2PO4 1.04, MgSO4 
0.83, NaHCO3 19, glucose 5.5; pH 7.4. The blood vessels were cleaned of connective tissue 
and cut into 2 mm rings. The endothelial lining was removed from one or two segments by 
gentle rubbing. The rings were suspended isometrically between two stainless steel hooks in 
organ chambers containing Krebs solution at 37°C, and the top hook was connected to a 
force-displacement transducer connected to an amplifier (Bionic instrument; Phymep, France) 
and a data acquisition system (PowerLabTM; ADInstruments Ltd, Australia), for continuous 
recording of isometric tension. The rings were stretched in a stepwise manner and allowed to 
equilibrate at 500 mg load over a period of 1 hour. Functional integrity of the arterial rings 
was then challenged with KCl (60 mM), and the presence or absence of functional 
endothelium was assessed by acetylcholine (AC, 1µM)-induced relaxation of aortic rings 
preconstricted with phenylephrine (1 µM).  
In each group of animals, the influence of AICAR on vascular reactivity was measured in 
aortic rings pre-contracted with a submaximal concentration of phenylephrine (1 mM). After 
reaching a tension plateau value, increasing concentrations of AICAR (or adenosine in some 
cases) were administered. Each increase in AICAR concentration was made in the bath once a 
plateau of relaxation was reached (after about 30 minutes). In some experiments, the inhibitor 
of NO-synthase L-NMMA (30 mM) or the non selective adenosine receptor antagonist SPT 
(10 mM) and the A1 selective adenosine receptor antagonist DPSX (30 nM) were added to the 
bath before phenylephrine administration. Relaxation values were expressed as percentage 
decreases in phenylephrine-induced vasoconstriction.  
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 Western blot analysis 
Aortas from WT, AMPKa2-/- and AMPKa1-/- mice were isolated in Krebs buffer and cleaned 
of connective tissue. They were then opened longitudinally and endothelium was removed by 
gentle rubbing. Tissues were homogenized in a lysate buffer containing in mM HEPES 50, 
KCl 50, EDTA 1, EGTA 1, beta-glycerol-phosphate 5, orthovanadate 1, DTT 1, NaPPi 5, 
phenylmethylsulfonyl fluoride (PMFS) 2 (all from Sigma-Aldrich Chimie (Saint-Quentin 
Fallavier, France)), a cocktail of protease inhibitors (Calbiochem Set V EDTA free) and 0.1 
% Triton X-100. Twenty five µg of proteins were used for western blot detection of AMPK 
isoforms. Immunoblot protein levels of AMPK subunits were determined by using anti-
AMPKa1 and anti-AMPKa2 (a generous gift from G. Hardie), and anti pan-AMPK-a (Cell 
Signaling Technology Inc, Danvers USA) antibodies. For the control of phosphorylation, 
C57Bl6 mice denuded aortas were incubated for 30 minutes in 0, 0.1 or 3 mM AICAR. 
Tissues were homogenized as above. Immunoblot protein levels of total and phosphorylated 
AMPK were determined by using the anti pan-antibody and anti phosphorylated antibody 
(Cell Signaling). The signals were detected by an ECL-based detection system. Band 
intensities were quantified by scanning and processing with the program Image J (v1.37 for 
Mac OSX). 
 
 Statistical analysis 
The results are expressed as mean ± S.E.M. The differences between groups were determined 
by two way analysis of variance (ANOVA) with repeated measures followed by the 
Bonferroni-corrected t-test or by Student’s t-test for paired or unpaired data as appropriate. 
All differences were considered significant when P < 0.05. 
 
RESULTS 
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In preliminary experiments conducted using C57Bl6 mice, a large range of AICAR 
concentrations (1 mM to 3 mM) was tested on phenylephrine-preconstricted mouse aortic 
rings (Figure 1A-C). AICAR dose-dependently induced aortic ring vasorelaxation at a 
concentration of 0.1mM and above (ANOVA, P<0.001, n= 7). The maximal effect obtained 
with AICAR (3 mM) was a 74.8±5.4% relaxation of the phenylephrine-induced contraction. 
These effects developed slowly and stabilized within 30 min after each addition of AICAR. 
Relaxing effects did not result from the decrease in phenylephrine– induced contraction 
amplitude, as shown in Figure 1B-C. Because AMPK is known to phosphorylate eNOS, we 
investigated the effects of L-NMMA, a known inhibitor of NOS. Surprisingly, AICAR-
induced vasorelaxation was not affected by treatment with 30µM L-NMMA or by the absence 
of endothelium (Figure 1C). This suggests that AICAR induced vasorelaxation is eNOS and 
endothelium independent. The effects of AICAR on the phosphorylation of AMPK were 
verified by Western blotting in denuded aortas (Figure 2). AMPK was partially 
phosphorylated after incubating the aortas with 0.1 mM AICAR and clearly phosphorylated 
with 3 mM AICAR. AICAR concentrations of 0.1 mM, 1 mM and 3 mM were used for 
subsequent experiments. 
The contraction amplitude of aortic rings preconstricted with 1 mM phenylephrine did not 
differ between AMPKa1-/-, AMPKa2-/- mice and their littermate controls (in g: 0.49 ± 0.02 
for C57Bl6, 0.52 ± 0.06 for WT AMPKa1, 0.41 ± 0.05 for AMPKa1-/-, 0.45 ± 0.05 for WT 
AMPKa2 and 0.42 ± 0.03 for AMPKa2-/- mice). As shown in Figure 3A, AICAR dose-
dependently relaxed preconstricted AMPKa1+/+ aortic rings (ANOVA, P< 0.001, n=5). In 
order to ensure that the relaxation effect of AICAR was not due to an adenosine like effect, 
we tested the effects of two adenosine receptor antagonists, SPT (10 mM) plus DPSX (30 
nM), on the AICAR dependent relaxation. The relaxation induced by AICAR (0.1, 1, 3 mM) 
was not altered by pre-incubation of the rings with SPT+DPSX (Figure 3A). We then tested 
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the ability of increasing concentrations of adenosine to relax aortic rings. The addition of 100 
µM adenosine had no significant effect on the contraction induced by phenylephrine (tension: 
0.896 ± 0.059 g without versus 0.914 ± 0.107 g with 100 µM adenosine, n= 5). Accordingly, 
the phenylephrine-induced contraction was not altered by 100 µM adenosine in the presence 
of SPT+DPSX (tension: 0.918 ± 0.085 g without versus 0.918±0.118 g with adenosine + 
SPT+DPSX). This shows that the AICAR effects were not due to a non specific adenosine 
receptor activation. As previously observed in C57Bl6 mice, AICAR-induced vasorelaxation 
was also not affected by the absence of endothelium or by treatment with 30µM L-NMMA. 
Taken together, these results show that the aortic vasorelaxation induced by AICAR was 
neither endothelium- nor NO-dependent in AMPKa1+/+ mice (Figure 3A).  
When tested on AMPKa1-/- mouse aorta, AICAR did not relax preconstricted aortic rings, 
suggesting that AICAR relaxes mouse aortic rings via AMPKa1 subunit activation (Figure 
3B). These effects were not associated with a difference in phenylephrine-induced aortic 
preconstriction, as stated above. Moreover, the absence of any AICAR effect was also 
observed after treatment with 10 µM SPT plus 30 nM DPSX. In the same tissues, removal of 
endothelium and L-NMMA ring incubation, revealed a small vasorelaxing effect for 3mM 
AICAR (29.3% ± 6.0%. and 21.2% ± 7.3%, respectively, P< 0.05 and P< 0.01 vs controls; 
Figure 3B). 
To further explore the involvement of each isoform of the AMPK catalytic subunits on 
AICAR-induced aortic relaxation, the same experiments were conducted on AMPKa2-/- and 
littermate AMPKa2+/+ mice. As shown in Figure 4A, AICAR induced concentration-
dependent vasorelaxation of preconstricted AMPKa2+/+ aortic rings (ANOVA, P< 0.001, 
n=5), although the sensitivity to AICAR was reduced in these mice since there was almost no 
relaxation with 0.1 mM AICAR. These relaxing effects were similar to those in AMPKa1+/+ 
mice, in terms of the delay of action and time of stabilization. Maximal relaxation was 
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obtained with 3 mM AICAR (80.6% ± 8.9% in AMPK2+/+ aortas; Figure 4A). The two 
adenosine receptor antagonists, 10 µM SPT plus 30 nM DPSX, did not modify these effects. 
As shown in Figure 4A, AICAR-induced aortic vasorelaxation was significantly increased in 
the presence of 30 mM L-NMMA for 1 mM AICAR (P< 0.01), and in the absence of 
endothelium for 0.1 mM and 1 mM AICAR (P< 0.001 and P< 0.01, respectively). In 
AMPKa2-/- mice, AICAR also induced a concentration-dependent vasorelaxation (ANOVA, 
P< 0.001, Emax= 88.2% ± 5.7%, Fig. 4B) that was not different from the one observed in their 
littermate controls, again indicating that the a2 subunit is not implicated in the vasorelaxation 
induced by AICAR. In this group, the relaxing effects of AICAR were not altered by pre-
incubation of the rings with the two adenosine receptor antagonists, 10 mM SPT plus 30 nM 
DPSX, showing that this relaxation was not associated with adenosine receptor activation 
(Figure 4B). Furthermore, neither the absence of endothelium nor 30 mM L-NMMA treatment 
reduced the AICAR-induced relaxation.  
In an attempt to identify the reason for the AMPK isoform specificity of the AICAR response, 
we determined the expression of the AMPK catalytic subunits in denuded aorta (Figure 5). As 
expected, AMPKa1 was present in WT and AMPKa2-/- aorta and absent in AMPKa1-/- aorta, 
thus showing that endothelium-free mouse aorta expresses the a1 subunit (Figure 5A). 
Similarly, AMPKa2 was observed in WT and AMPKa1-/- aorta but not in AMPKa2-/- aorta, 
showing that a2 subunit is also expressed in vascular smooth muscle. To determine the 
relative expression of AMPKa2 and AMPKa1 subunits, we performed immunoblots on 
denuded aorta from AMPKa1+/+ and AMPKa1-/- animals on the one hand, from AMPKa2+/+ 
and AMPKa2-/- animals on the other hand, using anti pan AMPKa antibody, which 
recognizes both a1 and a2 subunits of AMPK (Figure 5B, D). In figure 5B, the 63-kDa 
labelled protein band corresponds either to both a1 and a2 subunits in AMPKa1+/+ aorta 
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protein samples, or to remaining a2 subunit in AMPKa1-/- aorta protein samples. 
Quantification of signal intensity showed that a2 subunit expression levels in AMPKa1-/- 
denuded aorta accounted only for 20% of the total (a1 and a2) AMPK catalytic subunit 
expression (Figure 5C). In figure 5D, the 63-kDa labelled protein band corresponds either to 
both a1 and a2 subunits in AMPKa2+/+ aorta, or to remaining a1 subunit in AMPKa2-/- 
aorta. Quantification of signal intensity showed that a1 subunit expression levels in 
AMPKa2-/- denuded aorta accounted for 80% of the total (a1 and a2) AMPK catalytic 
subunit expression (Figure 5E). Taken together, these data clearly show that a1 subunit of 
AMPK is the predominant form expressed in denuded mouse aorta, confirming the data 
obtained previously with porcine carotid arteries (Rubin et al., 2005).  
 
DISCUSSION 
We investigated the potential vasorelaxing capacity of AMPK in mouse aortic rings. In this 
study we have shown that 1) AICAR, a pharmacological activator of AMPK, induces a dose- 
dependent relaxation of mouse aortic rings. 2) This effect is associated with AMPK 
phosphorylation. 3) It is independent of adenosine receptors. 4) It is also independent of 
endothelium and NOS activation. 5) The vasorelaxing effects of AICAR are completely 
abolished in AMPKa1 deficient mice but not in AMPKa2 deficient mice, showing that 
AICAR-induced aortic vasorelaxation depends on the AMPKa1 catalytic subunit.  
In aorta preconstricted with phenylephrine, AICAR dose-dependently induced vasorelaxation. 
This relaxation was slow but near-complete with 3 mM AICAR, and it was obtained in the 
four strains of mice that expressed the a1 AMPK subunit. The AICAR concentration needed 
for maximal relaxation was able to cause AMPK phosphorylation and was in a range already 
known to activate AMPK in different tissues (Morrow et al., 2003; Nagata et al., 2003). 
These results are in contrast to a study on porcine carotid rings prestimulated with endothelin-
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1, which exhibited only minor (@ 12%) relaxation in the presence of 2 mM AICAR, and 
without AMPK activation (Rubin et al., 2005). The same study found that metabolic 
challenge induced 100% relaxation associated with AMPK activation. The reason why 
AICAR failed to activate AMPK in porcine carotid arteries in contrast to mouse aorta could 
be due to species and/or vascular bed differences. Normally, AICAR enters cells and is 
metabolized to ZMP, an intermediate in the pathway of de novo purine synthesis. ZMP can be 
further metabolized, suggesting that its accumulation will depend on the balance between 
synthesis and degradation rates, which may differ between tissues. 
Because AICAR is a nucleoside, we investigated whether AICAR or its metabolites exhibit 
adenosine like effects. It was recently shown in HUVEC that adenosine can by itself activate 
AMPK phosphorylation via an adenosine receptor independent pathway involving transport 
of adenosine across the cell membrane and its further conversion to AMP (da Silva et al., 
2006). We found that, adenosine did not exhibit significant vasorelaxing effects in mice 
aortas. Moreover, we used a combination of adenosine receptor inhibitors: 10 mM SPT, which 
is a non selective adenosine receptor antagonist known to inhibit adenosine-induced 
vasorelaxation (Lewis et al., 1994), and 30 nM DPSX, which is a more selective A1 receptor 
antagonist (Daly et al., 1985). In the presence of these adenosine receptor antagonists, 
AICAR was still able to relax precontracted aorta. This demonstrates that the effects of 
AICAR are independent of adenosine signalling, strongly supporting the idea that AMPK 
mediates AICAR-induced vasorelaxation in mouse aorta. 
The endothelium regulates vascular tone through the synthesis and release of vasoactive 
compounds that mediate relaxation as well as contraction of vessels. The main relaxing factor 
is NO derived from endothelial NO-synthase. It has now been established that AMPK is able 
to phosphorylate and thereby activate eNOS, increasing NO production.  
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Surprisingly, when aortic rings were freed from endothelium by gentle rubbing, AICAR still 
induced vasorelaxation, suggesting that its effects were not mediated by the endothelium. 
Moreover, preincubation of aorta with L-NMMA, an inhibitor of NO-synthase, failed to block 
AICAR-induced vasorelaxation, suggesting that neither endothelial nor smooth muscle NOS 
were involved in the vasorelaxing effects of AICAR. Interestingly, the agent metformin, 
which acts at least in part through activation of AMPK (Davis et al., 2006; Zou et al., 2004), 
also relaxed endothelium-denuded or L-NAME-treated rat aortic rings pre-contracted with 
phenylephrine (Majithiya & Balaraman, 2006). Taken together these results suggest that 
AMPK can induce vasorelaxation in an endothelium- and NOS-independent manner, by a 
direct action on smooth muscle cells.  
To confirm the involvement of AMPK in the vasorelaxing effects of AICAR, and to 
investigate isoform specificity, experiments were repeated in AMPKa1 or a2 knock-out 
mice. The vasorelaxing effects of AICAR were completely abolished in a1 but not in a2 
deficient mice. Others have shown that both metformin and AICAR significantly increase 
eNOS Ser1179 phosphorylation in wild-type but not in AMPKa1-/- treated mice, indicating 
that AMPKa1 is the main isoform in mouse aorta (Davis et al., 2006). By contrast, another 
study showed that AICAR increased both a1 and a2 associated AMPK activity in pulmonary 
artery smooth muscle cells, although it increased AMPKa1 activity to a greater extent than 
AMPKa2 activity (Evans et al., 2005). In our study, immunoblots of endothelium-freed 
aortas revealed that the AMPKa1 subunit is present in WT and AMPKa2-/- mice, while the 
AMPKa2 isoform is expressed at a lower level. Consistent with this, it was previously shown 
that there was little if any AMPKa2 subunit in carotid smooth muscle (Rubin et al., 2005). 
Thus, the relaxing effects of AICAR on aortic rings of AMPKa2-/- mice seem to be due to the 
presence of AMPKa1 subunit in this tissue. The small potentiation of AICAR-induced 
relaxation observed in denuded aorta or in the presence of L-NMMA seems to depend on the 
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mouse strain, as it was absent in a1+/+, slight in C57Bl6 and more important in a2+/+ mice. 
Moreover, the effect disappeared in a2-/- mice while it was revealed in a1-/- mice only for 
high AICAR concentrations. This would suggest a slight AMPKa2-dependent endothelium-
mediated vasoconstricting effect. Taken together, these results show that AMPK is able to 
induce aortic ring relaxation through direct activation of AMPKa1 in smooth muscle cells. 
Smooth muscle contraction and relaxation depend on the phosphorylation state of the smooth 
muscle myosin regulatory light chain (MLC). Contraction is initiated by Ca-dependent 
activation of the MLC kinase, and by Rho kinase- and PKC-dependent inhibition of MLC-
phosphatase (MLCP). Relaxation of smooth muscle cell depends on calcium withdrawal, 
calcium desensitization, MLCP activation and/or MLCK inhibition (Somlyo & Somlyo, 
2003). For example, hypoxia which was shown to involve AMPK phosphorylation and 
activation (Rubin et al., 2005), can induce vasorelaxation by calcium- dependent mechanisms 
involving regulation of potassium channels (Thorne et al., 2004), or by calcium-independent 
mechanism involving activation of MLCP, and dephosphorylation of the Rho-kinase 
phosphorylated myosin binding subunit of MLCP (MYPT1) (Wardle et al., 2006). More work 
is needed to establish whether AICAR-induced activation of AMPK can interfere with 
calcium homeostasis, or the phosphorylation/dephosphorylation cascade of MLC, how and at 
which step. 
In summary, the present results show that activation of smooth muscle cell AMPKa1 subunit 
but not a2 induces a dose-dependent vasorelaxation of mouse aorta that is independent of NO 
and the presence of endothelium. As a metabolic sensor, vascular AMPK could be involved in 
the metabolic regulation of blood flow. Hypoxia increases the AMP/ATP ratio in pulmonary 
artery smooth muscle cells and induces a two-fold increase in AMPK activity (Evans et al., 
2005). Metabolic challenge also rapidly and reversibly activates AMPKa1 in porcine carotid 
arteries (Rubin et al., 2005), suggesting that AMPK activation may participate in the 
H
AL author m
anuscript    inserm
-00151009, version 1
H
AL author m
anuscript    inserm
-00151009, version 1
 15 
regulation of blood pressure. Indeed, AICAR treatment decreased blood pressure in rats 
displaying features of the insulin resistance syndrome (Buhl et al., 2002). AMPK activation 
may be an additional mechanism by which hypoxia or metabolic challenge can induce 
vasorelaxation of large vessels, thereby increasing oxygen availability in peripheral tissues. 
AMPK thus appears as a new player in the complex signaling pathways that regulate vascular 
tone. 
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FIGURE LEGENDS 
Figure 1: (A) Representative tension trace showing the effects of AICAR (1mM- 3 mM) on 
isolated C57Bl6 mouse aortic ring after phenylephrine-induced contraction. (B) 
Representative tension trace showing the stability of phenylephrine-induced contraction. (C) 
Mean values of AICAR (1mM- 3 mM)- induced relaxation of phenylephrine preconstricted 
C57Bl6 aortic rings (control conditions), and the same experiment in the presence of L-
NMMA (30 mM), or after removal of the endothelium. Data were analyzed by nonlinear 
regression sigmoidal dose-response curve using the Prism 4.01 software (GraphPad Software, 
San Diego, CA). Results are expressed as mean ± SEM of 4 to 7 mice aorta.  
Figure 2: Phosphorylation of AMPK by AICAR in denuded C57Bl6 mouse aorta. 
Immunoblots showing expression level of total AMPKa (anti panAMPKa antibody) and 
phosphorylated AMPK (anti phosphoAMPK antibody), after 30 min incubation in AICAR 0, 
0.1 or 3 mM. Twenty five µg of protein from C57Bl6 mice aortic rings were loaded in each 
lane. N=3-4 different animals in each group.  
Figure 3: Representative tension traces (left) and mean values (right) showing the effects of 
AICAR (0.1, 1, 3 mM) on isolated AMPKa1+/+ (A)  and AMPKa1-/- (B) mouse aortic ring 
after phenylephrine-induced contraction, in the absence or in the presence of SPT (10 mM) 
plus DPSX (30 nM), L-NMMA (30 mM), or after removal of the endothelium. Results are 
expressed as mean ± SEM of 4 to 6 mice aorta. * P< 0.05, ** P<0.01 vs control conditions. 
Figure 4: Mean values of AICAR (0.1, 1, 3 mM)-induced relaxation of preconstricted AMPK 
a2+/+ (A) and AMPKa2-/- mouse (B) aortic rings under control conditions, in the presence of 
SPT (10 mM) plus DPSX (30 nM), L-NMMA (30 mM), or after removal of the endothelium. 
Results are expressed as mean ± SEM of 4 to 6 mice aorta. * P< 0.05, ** P<0.01 and *** 
P<0.001 vs control conditions.  
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Figure 5: AMPK catalytic subunit isoforms in mouse-denuded aorta. (A) Immunoblots 
showing expression pattern for AMPKa1 (upper blot) and AMPKa2 (lower blot) subunit 
levels. Lane 1, mouse liver (used as control); lanes 2-4, mouse AMPKa2+/+ aorta; lanes 5-7, 
mouse AMPKa2-/- aorta, lanes 8-10, mouse AMPKa1+/+ aorta; lanes 11-13, mouse AMPKa1-
/- aorta. Twenty five µg of protein from WT, AMPKa1-/- and AMPKa2-/- mouse denuded 
aortic rings, were loaded in each lane. (B) AMPKa subunit expression in AMPKa1+/+ and 
AMPKa1-/- denuded aorta detected by anti panAMPKa antibody. Lane 1, mouse liver (used 
as control), lanes 2-4, mouse AMPKa1+/+ aorta; lanes 5-7, mouse AMPKa1-/- aorta. (C) 
Quantification of AMPKa subunit expression levels in AMPKa1+/+ and AMPKa1-/- aorta 
(n=5 different animals in each group). AMPKa expression has been normalized to the value 
observed in AMPKa1+/+ aorta. *** P<0.001. (D) AMPKa subunit expression in AMPKa2+/+ 
and AMPKa2-/- denuded aorta detected by anti panAMPKa antibody. Lane 1, mouse liver 
(used as control), lanes 2-4, mouse AMPKa2+/+ aorta; lanes 5-7, mouse AMPKa2-/- aorta. (E) 
Quantification of AMPKa subunit expression levels in AMPKa2+/+ and AMPKa2-/- aorta 
(n=5 different animals in each group). AMPKa expression has been normalized to the value 
observed in AMPKa2+/+ aorta. * P<0.05, ** P< 0.01. 
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Figure 3
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